Search results
Found 12 matches for
Akbar Group: Extracellular Vesicles in Cardiovascular, Inflammatory and Metabolic Disease
The Akbar Lab is interested in defining the therapeutic and diagnostic potential of extracellular vesicles for immunomodulation and precision medicine in cardiovascular, metabolic, and inflammatory diseases.
Chakraverty Group: Haematopoietic Transplantation and Immunotherapy
- Cell and Gene Therapy
- MRC Molecular Haematology Unit
- MRC Weatherall Institute of Molecular Medicine
- Nuffield Division of Clinical Laboratory Sciences
Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.
Davies Group: Genomics and Clinical Genome Editing
- Cell and Gene Therapy
- MRC Molecular Haematology Unit
- MRC Weatherall Institute of Molecular Medicine
- Nuffield Division of Clinical Laboratory Sciences
We are primarily interested in understanding how the genome functions and to leverage this to develop novel genome editing based cellular therapies
Vyas Group: Biology and Treatment of Human Myeloid Cancers
- Cell and Gene Therapy
- MRC Molecular Haematology Unit
- MRC Weatherall Institute of Molecular Medicine
- Nuffield Division of Clinical Laboratory Sciences
We aim to understand the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.
Gill and Hyde Group: Gene Medicine Group
We are developing gene therapy for lung conditions, including the genetic disease Cystic Fibrosis (CF) and neonatal lung conditions such as surfactant protein B (SPB) deficiency. We are also evaluating whether the lung can be used as a ‘protein factory’ to make therapeutic proteins such as antibodies.
Watkins Group: Inherited Heart Muscle Disease Group
Using human genetics and functional genomics to understand inherited heart disease